Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Allogeneic NK Cell Therapy for Elderly AML
NCT04599452Phase 2Unknown
- Sponsor
- Second Hospital of Shandong University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AlloNK in acute myeloid leukemia (AML), sponsored by Second Hospital of Shandong University. Status: unknown.
02
Drugs
AlloNK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04599452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599452.